ArticleFrontiers in medicine2026
Predicting comorbidities in psoriasis using TCM constitution and multimodal data: a prospective cohort study protocol.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic inflammatory skin disease associated with multiple systemic comorbidities. Patients exhibit considerable individual variability in response to systemic therapies, making treatment outcomes and adverse reactions difficult to predict. Traditional Chinese Medicine (TCM) constitution theory may explain this variability, but prospective validation is lacking. This study primarily aims to evaluate the predictive value of TCM constitution types and multimodal clinical data for comorbidity risk in patients with psoriasis. As a secondary objective, it will also explore the association between TCM constitution and systemic treatment effectiveness and adverse events. Methods: This is a multicenter, prospective, observational cohort enrolling 1000 adults (≥18 years) with psoriasis who are scheduled to initiate systemic therapy. Over a 52-week period, we will collect comprehensive data on TCM constitution types, syndrome patterns, and multimodal clinical data. All participants will be followed to monitor comorbidity progression and, secondarily, to assess the effectiveness of systemic therapies and record adverse events. Discussion: By leveraging a digitized platform for TCM and clinical data collection, this prospective study aims to validate the relationship between TCM constitution types and psoriasis comorbidities and, secondarily, treatment responses. The ultimate objective is to build integrated predictive models for comorbidity risk as the primary outcome and treatment outcomes as secondary endpoints, combining TCM-based features with modern clinical indicators to advance personalized medicine in psoriasis. Ethics and dissemination: The study protocol was approved by the Medical Ethics Review Committee of The Second Affiliated Hospital of Hunan University (ID: 2025-KY-036-01) and the Medical Ethics Review Committee of Xiangya Hospital, Central South University (ID: 2025122317). Study results will be published in peer-reviewed journals and presented at national and international conferences. In addition, lay summaries of the findings will be made available to participants and the public via the hospitals' websites and other public forums. Clinical trial registration: https://www.chictr.org.cn/searchprojEN.html, identifier [ITMCTR2025002518].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.